Tonix Pharmaceuticals announces presentation at ACS of next-gen oxytocin

Tonix Pharmaceuticals announces a poster presentation at the American Chemistry Society, ACS, Spring 2024 Meeting, held March 17-21, 2024, in New Orleans, Louisiana. The poster presentation titled, Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations, describes the discovery and characterization of novel oxytocin analogues that are candidate treatments for craniofacial pain, excessive eating, and endocrinological conditions including bone health in autism and insulin resistance. “Intranasal oxytocin has several potential therapeutic applications,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Preclinical studies have shown that oxytocin, a hypothalamic peptide hormone, simultaneously reduces food intake and increases energy expenditure, leading to weight loss.1-3 Intranasal oxytocin is well-tolerated and in published studies of adults, results in reduced caloric intake, increased fat burning and improved insulin sensitivity.1-3”